Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Sage Therapeutics, Inc. (SAGE) reported a Q4 loss of $1.56 per share, missing the Zacks Consensus Estimate of a $1.45 loss. This is a larger loss compared to $0.55 per share a year ago.
February 11, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics reported a larger-than-expected Q4 loss of $1.56 per share, missing the consensus estimate and showing a significant increase from the previous year's loss.
The reported loss per share of $1.56 is worse than the expected $1.45, indicating underperformance. The increase from last year's $0.55 loss suggests deteriorating financial health, likely leading to negative short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100